Robert W. Baird Lowers ICON Public (NASDAQ:ICLR) Price Target to $340.00

ICON Public (NASDAQ:ICLR) had its target price cut by analysts at Robert W. Baird from $368.00 to $340.00 in a report released on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price target would suggest a potential upside of 12.99% from the company’s current price.

Several other equities analysts have also recently commented on the stock. Leerink Partners began coverage on shares of ICON Public in a report on Wednesday. They issued an “outperform” rating and a $379.00 price target for the company. Barclays reduced their target price on shares of ICON Public from $355.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a report on Friday, May 31st. Truist Financial reaffirmed a “buy” rating and issued a $383.00 target price on shares of ICON Public in a research report on Wednesday, September 11th. Finally, The Goldman Sachs Group began coverage on ICON Public in a research note on Thursday, June 6th. They set a “buy” rating and a $370.00 price objective for the company. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $351.60.

ICON Public Stock Down 0.5 %

ICLR opened at $300.92 on Friday. ICON Public has a twelve month low of $221.20 and a twelve month high of $347.72. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. The business has a 50 day moving average price of $318.32 and a 200 day moving average price of $318.51. The firm has a market cap of $24.82 billion, a P/E ratio of 36.61, a price-to-earnings-growth ratio of 1.29 and a beta of 1.22.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The company had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same period in the prior year, the company earned $2.96 earnings per share. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. Research analysts forecast that ICON Public will post 14.54 EPS for the current year.

Institutional Trading of ICON Public

Institutional investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC increased its stake in ICON Public by 0.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 695,932 shares of the medical research company’s stock valued at $196,998,000 after buying an additional 6,331 shares during the last quarter. State of Tennessee Treasury Department grew its stake in shares of ICON Public by 4.9% in the fourth quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company’s stock valued at $44,101,000 after buying an additional 7,270 shares in the last quarter. Livelsberger Financial Advisory acquired a new position in ICON Public during the fourth quarter worth $29,000. GAMMA Investing LLC raised its position in ICON Public by 22.5% during the first quarter. GAMMA Investing LLC now owns 174 shares of the medical research company’s stock worth $58,000 after acquiring an additional 32 shares in the last quarter. Finally, Steph & Co. lifted its stake in ICON Public by 11.2% in the first quarter. Steph & Co. now owns 1,852 shares of the medical research company’s stock valued at $622,000 after acquiring an additional 186 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.